You can buy or sell BeiGene and other stocks, options, ETFs, and crypto commission-free!
BeiGene, Ltd. American Depositary Shares, also called BeiGene, is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. Read More It focuses on Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317), and Pamiparib (BGB-290). The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Beijing, China. The listed name for BGNE is BeiGene, Ltd. American Depositary Shares.
52 Week High
52 Week Low
— per share
Expected Nov 9